Syndax Pharmaceuticals, Inc. Stock-Based Compensation
Syndax Pharmaceuticals, Inc. (SNDX) reported Stock-Based Compensation of $26.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $14.01M, a 1.64% increase year-over-year.
- Syndax Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $12.05M, a 16.13% increase year-over-year.
- Syndax Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $11.25M, a 8.48% decline year-over-year.
- Syndax Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $12.08M, a 1.24% increase year-over-year.
- Syndax Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $47.50M, a 10.41% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $43.03M, a 39.01% increase from fiscal 2023.
- Syndax Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $30.95M, a 93.21% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $16.02M, a 20.29% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $26.07M 10-Q · filed 2026-08-04 | $37.32M derived: sum of 3 quarters · filed 2026-08-04 | $49.40M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $12.05M 10-Q · filed 2026-04-30 | $23.31M derived: sum of 2 quarters · filed 2026-04-30 | $35.39M derived: sum of 3 quarters · filed 2026-04-30 | $49.18M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $11.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $23.34M derived: sum of 2 quarters · filed 2026-02-26 | $37.12M derived: sum of 3 quarters · filed 2026-08-04 | $47.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | $12.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $25.87M derived: sum of 2 quarters · filed 2026-08-04 | $36.25M 10-Q · filed 2025-11-03 | $48.55M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $13.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $24.17M 10-Q · filed 2026-08-04 | $36.46M derived: sum of 3 quarters · filed 2026-08-04 | $48.40M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $10.38M 10-Q · filed 2026-04-30 | $22.68M derived: sum of 2 quarters · filed 2026-04-30 | $34.61M derived: sum of 3 quarters · filed 2026-04-30 | $44.51M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $12.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.23M derived: sum of 2 quarters · filed 2026-02-26 | $34.13M derived: sum of 3 quarters · filed 2026-02-26 | $43.03M 10-K · filed 2026-02-26 |
| 2024-09-30 | $11.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $21.83M derived: sum of 2 quarters · filed 2025-11-03 | $30.73M 10-Q · filed 2025-11-03 | $39.06M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $9.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $18.80M 10-Q · filed 2025-08-04 | $27.12M derived: sum of 3 quarters · filed 2026-02-26 | $35.44M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $8.90M 10-Q · filed 2025-05-05 | $17.23M derived: sum of 2 quarters · filed 2026-02-26 | $25.55M derived: sum of 3 quarters · filed 2026-02-26 | $33.61M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $8.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.65M derived: sum of 2 quarters · filed 2026-02-26 | $24.71M derived: sum of 3 quarters · filed 2026-02-26 | $30.95M 10-K · filed 2026-02-26 |
| 2023-09-30 | $8.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $16.39M derived: sum of 2 quarters · filed 2024-11-05 | $22.62M 10-Q · filed 2024-11-05 | $26.86M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $8.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $14.30M 10-Q · filed 2024-08-01 | $18.54M derived: sum of 3 quarters · filed 2025-03-03 | $22.91M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $6.24M 10-Q · filed 2024-05-08 | $10.48M derived: sum of 2 quarters · filed 2025-03-03 | $14.84M derived: sum of 3 quarters · filed 2025-03-03 | $18.78M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $4.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $8.60M derived: sum of 2 quarters · filed 2025-03-03 | $12.54M derived: sum of 3 quarters · filed 2025-03-03 | $16.02M 10-K · filed 2025-03-03 |
| 2022-09-30 | $4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $8.30M derived: sum of 2 quarters · filed 2023-11-02 | $11.78M 10-Q · filed 2023-11-02 | $15.71M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $3.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $7.42M 10-Q · filed 2023-08-03 | $11.35M derived: sum of 3 quarters · filed 2024-02-27 | $14.73M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $3.48M 10-Q · filed 2023-05-08 | $7.41M derived: sum of 2 quarters · filed 2024-02-27 | $10.79M derived: sum of 3 quarters · filed 2024-02-27 | $14.03M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $3.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $7.31M derived: sum of 2 quarters · filed 2024-02-27 | $10.55M derived: sum of 3 quarters · filed 2024-02-27 | $13.32M 10-K · filed 2024-02-27 |
| 2021-09-30 | $3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $6.62M derived: sum of 2 quarters · filed 2022-11-03 | $9.39M 10-Q · filed 2022-11-03 | $11.42M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $3.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $6.01M 10-Q · filed 2022-08-08 | $8.04M derived: sum of 3 quarters · filed 2023-02-28 | $11.11M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $2.77M 10-Q · filed 2022-05-09 | $4.80M derived: sum of 2 quarters · filed 2023-02-28 | $7.87M derived: sum of 3 quarters · filed 2023-02-28 | $9.99M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $5.10M derived: sum of 2 quarters · filed 2023-02-28 | $7.23M derived: sum of 3 quarters · filed 2023-02-28 | $9.06M 10-K · filed 2023-02-28 |
| 2020-09-30 | $3.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $5.19M derived: sum of 2 quarters · filed 2021-11-15 | $7.02M 10-Q · filed 2021-11-15 | $8.55M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $3.96M 10-Q · filed 2021-08-09 | $5.48M derived: sum of 3 quarters · filed 2022-03-01 | $7.03M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $1.83M 10-Q · filed 2021-05-11 | $3.35M derived: sum of 2 quarters · filed 2022-03-01 | $4.90M derived: sum of 3 quarters · filed 2022-03-01 | $6.24M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.08M derived: sum of 2 quarters · filed 2022-03-01 | $4.41M derived: sum of 3 quarters · filed 2022-03-01 | $6.00M 10-K · filed 2022-03-01 |
| 2019-09-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.89M derived: sum of 2 quarters · filed 2020-11-05 | $4.48M 10-Q · filed 2020-11-05 | $5.95M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.93M 10-Q · filed 2020-08-06 | $4.40M derived: sum of 3 quarters · filed 2021-03-12 | $6.14M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $1.59M 10-Q · filed 2020-05-07 | $3.06M derived: sum of 2 quarters · filed 2021-03-12 | $4.80M derived: sum of 3 quarters · filed 2021-03-12 | $6.37M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $3.21M derived: sum of 2 quarters · filed 2021-03-12 | $4.78M derived: sum of 3 quarters · filed 2021-03-12 | $6.20M 10-K · filed 2021-03-12 |
| 2018-09-30 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $3.31M derived: sum of 2 quarters · filed 2019-11-07 | $4.73M 10-Q · filed 2019-11-07 | $6.01M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $2.99M 10-Q · filed 2019-08-07 | $4.27M derived: sum of 3 quarters · filed 2020-03-05 | $5.62M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | $1.42M 10-Q · filed 2019-05-08 | $2.70M derived: sum of 2 quarters · filed 2020-03-05 | $4.05M derived: sum of 3 quarters · filed 2020-03-05 | $5.49M derived: sum of 4 quarters · filed 2020-03-05 |
| 2017-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $2.63M derived: sum of 2 quarters · filed 2020-03-05 | $4.07M derived: sum of 3 quarters · filed 2020-03-05 | $5.45M 10-K · filed 2020-03-05 |
| 2017-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $2.79M derived: sum of 2 quarters · filed 2018-11-05 | $4.17M 10-Q · filed 2018-11-05 | $5.12M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $2.83M 10-Q · filed 2018-08-08 | $3.77M derived: sum of 3 quarters · filed 2019-03-07 | $4.56M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $1.38M 10-Q · filed 2018-05-09 | $2.32M derived: sum of 2 quarters · filed 2019-03-07 | $3.12M derived: sum of 3 quarters · filed 2019-03-07 | $3.90M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $947.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $1.74M derived: sum of 2 quarters · filed 2019-03-07 | $2.52M derived: sum of 3 quarters · filed 2019-03-07 | $4.71M 10-K · filed 2019-03-07 |
| 2016-09-30 | $792.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $1.57M derived: sum of 2 quarters · filed 2017-11-08 | $3.76M 10-Q · filed 2017-11-08 | $4.93M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $779.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $2.97M 10-Q · filed 2017-08-10 | $4.14M derived: sum of 3 quarters · filed 2018-03-08 | $5.43M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $2.19M 10-Q · filed 2017-05-09 | $3.36M derived: sum of 2 quarters · filed 2018-03-08 | $4.65M derived: sum of 3 quarters · filed 2018-03-08 | $5.75M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $2.46M derived: sum of 2 quarters · filed 2018-03-08 | $3.56M derived: sum of 3 quarters · filed 2018-03-08 | $3.88M 10-K · filed 2018-03-08 |
| 2015-09-30 | $1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $2.39M derived: sum of 2 quarters · filed 2016-11-14 | $2.71M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $1.42M 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $324.00K 10-Q · filed 2016-05-16 | |||
| 2014-12-31 | $2.26M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |